<DOC>
	<DOCNO>NCT01417533</DOCNO>
	<brief_summary>Background : - Hereditary inclusion body myopathy ( HIBM ) disease cause walk difficulty increase muscle weakness . It usually develop young adult ( 20 30 year age ) , affect arm leg muscle . HIBM cause mutation gene may affect muscle function . Researchers want learn cause , symptom , effect HIBM . Objectives : - To collect genetic medical information people hereditary inclusion body myopathy . Eligibility : - Individuals 18 80 year age hereditary inclusion body myopathy use wheelchair . - Participants must willing stop current treatment HIBM enrol study . Design : - Participants screen medical history , physical exam , neurological exam . - At first visit , participant follow test : - Questionnaires impact HIBM daily activity , mood , quality life - 24-hour urine collection - Blood sample - Heart function test - Muscle strength endurance test , include walk - Imaging study muscle - Participants return followup visit 6 , 12 , 18 month . They may ask return final visit 24 month . Not test perform visit . - Treatment provide part protocol . For information , visit website : http : //hibmstudy.nhgri.nih.gov/</brief_summary>
	<brief_title>A Natural History Study Patients With GNE Myopathy</brief_title>
	<detailed_description>GNE myopathy , also know Hereditary Inclusion Body Myopathy ( HIBM ) autosomal recessive myopathy onset early adulthood characterize progressive muscle weakness . The causative gene , GNE , cod bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase ( GNE ) catalyze first two step biosynthesis sialic acid ( SA ) . The subsequent paucity SA production presume cause decrease sialylation GNE myopathy muscle glycoprotein , result muscle deterioration . To date , amount prospectively collect publish natural history data GNE myopathy minimal due rare nature disease . This natural history study seek characterize rate progression disease relate age onset . Additionally , study design elucidate functional outcome measure ( endpoint ) future therapeutic trial , correlate serum biomarkers muscle magnetic resonance imaging ( MRI ) find progression disease .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Distal Myopathies</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age 1880 year , either gender , inclusive . 2 . Diagnosis GNE myopathy base upon : 1 . Consistent clinical course , family history GNE myopathy characteristic finding muscle biopsy , 2 . Identification two GNE gene mutation . Molecular confirmation diagnosis obtain subject study . 3 . Subjects may take ManNAc time enrollment , must willing stop treatment ManNAc , sialic acid ( SA ) , intravenous immunoglobulin ( IVIG ) , and/or supplement contain SA ( e.g. , St John wort , sialyllactose ) screen assessment must willing remain treatment duration study . 4 . Ability travel NIH Clinical Center repeatedly admission . 5 . Subjects carrier family member caregiver patient study eligible participate . 6 . Must able provide inform consent . EXCLUSION CRITERIA : 1 . Inability travel NIH Clinical Center repeat evaluation . 2 . Psychiatric illness disease would interfere subject ability comply requirement protocol . 3 . Hepatic laboratory parameter ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , gammaGTP ) renal laboratory parameter ( creatinine , blood urea nitrogen [ BUN ] ) great 3 time upper limit normal . 4 . Presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , metabolic , gastrointestinal disease relate primary disease process .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2, 2017</verification_date>
	<keyword>Hereditary Inclusion Body Myopathy</keyword>
	<keyword>N-Acetyl-D-mannosamine ( ManNAc )</keyword>
	<keyword>UDP-N-acetyglucosamine 2-epimerase ( GNE )</keyword>
	<keyword>Sialic Acid</keyword>
	<keyword>Muscular Dystrophy</keyword>
	<keyword>HIBM</keyword>
</DOC>